Citations

Clear

3138 citation(s) found for "Smith, AM".

Leveraging Machine Learning to Predict Delayed Graft Function Occurrence and Length in Kidney Transplant Recipients
Nica, Alexandru , Mejia, Mateo Velasquez , Abdelrheem, Ahmed, Smith, Byron, Park, Walter D. , Stegall, Mark D. , Heilman, Raymond L. , Smith, Byron H. , Smith, Byron , Park, Walter , Stegall, Mark D , Heilman, Raymond , Jadlowiec, Caroline , Jadlowiec, Caroline C.

Mayo Clinic

Clinical Transplantation | March 23, 2026 | Volume: 40 | Issue: 3 | Pages: No page available

10.1111/ctr.70514 | PMID 41869992 Get It

ABSTRACT Predicting delayed graft function (DGF) relies on donor, recipient, and perioperative factors. Despite the growing recognition that DGF duration strongly influences patient outcomes, no models currently address or predict its impact—highlighting an important gap in current research and clinical practice. This study aimed to develop an ensemble‐based machine learning model using perioperative data to predict DGF occurrence and duration. The gradient‐boosted decision trees model was trained and validated on 2725 patients, with k‐fold cross‐validation in an external cohort of 284 patients. Model performance was evaluated based on accuracy, ROC‐AUC, and other metrics using R and Python libraries. The binary DGF prediction model achieved a ROC‐AUC of 0.77, while the DGF duration classification model had an accuracy of 79.2%. DGF duration AUC values by time interval were 0.76 for 0–1 weeks, 0.81 for >1–2 weeks, 0.80 for >2–3 weeks, and 0.87 for >3 weeks; the overall macro‐averaged AUC was 0.81. The mean Brier score for multi‐class predictions was 0.14. External validation showed a 78% accuracy for DGF duration prediction. Acute kidney injury (AKI) and donor donation after circulatory death (DCD) status were key DGF predictors. The use of gradient‐boosted decision trees (GBDT) improves the prediction of both the likelihood and duration of DGF, addressing a current gap in kidney transplant patient care. By facilitating personalized transplant care, this model supports more effective perioperative planning and timely interventions, which may contribute to better patient outcomes.
Injury Rates and Financial Dollars Lost Due to Injury Continue to Rise in Major League Baseball: An Analysis of Injured List Data Over 15 Seasons From 2010 to 2024
Kang, Louis , Meta, Fabien , Paparesta, Nick, Beacom, Amy S , Bowman, Eric N. , Smith, Matt, Camp, Christopher L. , Kang, Louis S

Mayo Clinic

Arthroscopy | March 20, 2026 | Volume: 42 | Issue: 3 | Pages: 598-609

10.1002/arj.70065 | PMID 41856490 Get It

Purpose To use publicly available injured list (IL) data to 1) describe Major League Baseball injury trends from 2010 to 2024; 2) analyze injury types and body regions affected to report the highest impact injuries; and 3) report the financial implications of time lost due to injury over this 15‐year period. Methods IL data for every Major League Baseball player (pitchers and position players) from the 2010 to 2024 regular seasons were collected using publicly available sources, including player demographics, IL placements, body part injured, and length of each IL stay. Player salaries were compiled to determine the “financial loss” per injury. Results Across 15 seasons, 8078 players were placed on the IL, totaling 478,085 days. The mean IL placements/year was 634, and the annual number increased by an additional 27 injuries/year ( P < .001). Mean total IL days/season was 31,872, and this increased year‐over‐year ( P = .008). Shoulder injuries represented the most IL placements (n = 1555), followed by elbow (n = 1344) and upper leg (n = 769). Elbow injuries averaged the most days missed/IL placement (mean: 93, median: 74) and the greatest total days missed (129,610), followed by shoulder (95,189). Pitchers comprised 55% of IL placements and most commonly injured their shoulder or elbow. Infielders and outfielders accounted for 21% and 16% of IL placements, respectively. A total financial loss of $9,636,753,291 was accumulated over 15 seasons. Financial loss increased season‐to‐season (+$32,309,178/year, P = .002). Elbow injuries accounted for the highest financial loss at $1,932,048,168 ($1,379,049 lost/injury). In 2024, $2,220,432 was lost/elbow injury, $1,110,573/shoulder injury, $1,397,322/any injury, and $952,973,760 total for the season. Conclusions This study observed that the number of players, IL placements, days spent on the IL, and financial loss due to injury increased steadily each year. Pitchers were the most frequently injured players with shoulder and elbow injuries being most common. Over the 15‐season study period, there was a total financial loss of nearly $9.7 billion due to salary paid to injured players, with elbow injuries contributing the highest loss at just under $2 billion. Clinical Relevance Injury trends and financial data from Major League Baseball highlight the growing burden of shoulder and elbow injuries, particularly in pitchers. These findings underscore the need for orthopaedic surgeons to focus on prevention, early intervention, and optimized surgical management of high‐impact injuries to reduce long‐term morbidity and associated financial costs at the elite level.
Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma
Abdallah, Nadine, White, Thomas, Heeren, Amanda A., Wildes, Tanya, Marar, Rosalyn, Yee, Claire , Bodily, Anna, Kotajarvi, Brian R., Aug, Sarah, Kapoor, Prashant , Dispenzieri, Angela, Hayman, Suzanne, Dingli, David, Gonsalves, Wilson, Cook, Joselle, Zanwar, Saurabh , Lin, Y., Kourelis, Taxiarchis, Gertz, MA, Warsame, Rahma, Rajkumar, S, LeBrasseur, Nathan, Kumar, Shaji, Weivoda, Megan , Abdallah, Nadine H , Heeren, Amanda, Marar, Rosalyn , Yee, Claire , Kotajarvi, Brian, Buadi, Francis K , Kapoor, Prashant , Dispenzieri, Angela , Dingli, David , Gonsalves, Wilson , Cook, Joselle M , Zanwar, Saurabh S , Binder, Moritz , Lin, Yi , Kourelis, Taxiarchis , Gertz, Morie A , Rajkumar, S Vincent , Sfeir, Jad G , Kumar, Shaji K , Weivoda, Megan , Abdallah, Nadine , Smith, Byron H. , Wildes, Tanya M. , Buadi, Francis K. , Dispenzieri, Angela , Hayman, Suzanne, Dingli, David , Gonsalves, Wilson I. , Cook, Joselle , Binder, Moritz , Kourelis, Taxiarchis , Warsame, Rahma , Sfeir, Jad , LeBrasseur, Nathan K

Mayo Clinic

No container title available | March 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8605152/v1 | PMID 41890848 Get It

Abstract Frailty predicts adverse outcomes in multiple myeloma (MM), yet an objective frailty biomarker is lacking. Circulating senescence-associated secretory phenotype (SASP) factors correlate with frailty and adverse outcomes in chronic diseases, but their relevance in MM is unclear. In this study, we investigated the relationship between 36 plasma SASP factors, frailty, and clinical outcomes in: (1) a historical cohort using stored specimens from 59 patients with newly diagnosed MM, and (2) a prospective cohort of 36 patients initiating new MM treatment. Several SASP factors were significantly associated with frailty after adjusting for age, sex, and body mass index; GDF-15, TNF-RI, IL-6, and IL-8 showed positive correlations with both cumulative-deficit based and physical frailty indices. Additionally, significant age-adjusted associations were observed between SASP factors and treatment outcomes, including overall survival (OS), high-grade toxicity, and healthcare utilization. We developed a 5-factor SASP model that demonstrated superior predictive performance for OS compared to chronological age, R-ISS stage, and clinical frailty, and TNF-RI alone (5-year OS AUC: 0.90). These findings highlight the association between senescence biomarkers and frailty and OS, and support further investigation of SASP factors as objective frailty biomarkers in MM.
Treatment Decision‐Making Roles and Preferences Among Adolescents and Young Adults With Cancer
Gutierrez, Amanda M. , Robinson, Jill O. , Allen‐Rhoades, Wendy , Canfield, Isabel, Hsu, Rebecca , Scollon, Sarah R., Desrosiers‐Battu, Lauren R., Schneider, Nicole M. , Lin, Frank Y. , Parsons, D. Williams , Majumder, Mary A. , Malek, Janet , McGuire, Amy L., Desrosiers, Lauren , Canfield, Isabel , Scollon, Sarah , Allen-Rhoades, Wendy A , Smith, Hadley S , Canfield, Isabel , Hsu, Rebecca L , Scollon, Sarah R , Desrosiers-Battu, Lauren R , Lin, Frank Y , Parsons, D Williams , Plon, Sharon E. , McGuire, Amy L

Mayo Clinic

Pediatric Blood & Cancer | March 19, 2026 | Volume: 73 | Issue: 6 | Pages: No page available

10.1002/1545-5017.70235 | PMID 41852319 Get It

ABSTRACT Background Decision‐making (DM) dynamics between adolescents and young adults (AYAs) with cancer, parents, and oncologists remain underexplored in diverse populations. We examined cancer treatment DM preferences among an ethnically and socioeconomically diverse group of AYAs and their parents. Procedure We surveyed AYAs with cancer ( n = 75) and their parents ( n = 52) participating in the Texas KidsCanSeq study. Among AYA‐parent pairs, we compared preferred and actual treatment DM roles. We explored associations among DM roles, having pediatric‐to‐adult care transition discussions, and clinical and sociodemographic characteristics. We report AYAs’ and parents’ preferences for involvement in shared decision‐making (SDM) with oncologists about cancer treatment. Results AYAs’ DM role preferences varied: 44% preferred to equally share DM with parents, 31% preferred AYA‐led DM, and 25% preferred parent‐led DM. Parents who preferred parent‐led DM had younger AYAs than parents who preferred equally shared DM ( p = 0.011). For actual DM, 48% of AYAs reported DM was equally shared, 24% reported DM was AYA‐led, and 28% reported DM was parent‐led. Most AYAs had their preferred role (73%). AYAs’ actual role did not significantly differ from their own or their parents’ preferences (both p > 0.05). Approximately half of AYAs reported recent pediatric‐to‐adult care transition discussions. AYAs’ DM preferences and participation in transition discussions did not significantly differ along clinical or sociodemographic characteristics (all p > 0.05). AYAs and parents perceived high importance across all aspects of SDM with oncologists. Conclusion In this diverse study population, AYAs desired engagement in treatment DM and SDM. Although specific role preferences varied, opportunities existed to increase discussion around pediatric‐to‐adult care transition.
Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS)
Al-Samkari, Hanny, Friday, Cassi , Kasthuri, R., Gossage, James R. , Murphy, Charles Griffin, Hountras, Peter, Kirkland, Kristi Jackson, Iyer, Vivek, Prasad, Vikas, Ahluwalia, Vaibhav, Rodriguez-Lopez, Josanna, Conrad, Miles , Hetts, S, Chakinala, Murali M. , Beasley, Melissa, Kirkpatrick, P., Lindquist, Jonathan , Battaile, John T., Lu, An, Parambil, Joseph G. , McCrae, KR, Sheynzon, V., Whitehead, Kevin, Sion, Cassidy, McWilliams, Justin P. , Cusumano, Lucas R. , Trerotola, Scott O. , Chesnutt, Mark S., Kaufman, Claire , Dickey, Melissa Ann, Krock, Nolie, Cottrill, Crystal, Competiello, Tania, Levy, Hara , Clancy, Marianne S. , Henderson, Katharine, Pollak, J., Iyer, Vivek , Al‐Samkari, Hanny , Kasthuri, Raj S. , Al-Samkari, Hanny , Kasthuri, Raj S , Murphy, Charles G , Iyer, Vivek N , Ahluwalia, Vaibhav , Rodriguez-Lopez, Josanna M , Conrad, Miles , Hetts, Steven , Ohliger, Michael , Sisk, Bryan A , Beasley, Melissa A , Lindquist, Jonathan , McCrae, Keith R , Whitehead, Kevin J , Cusumano, Lucas R , Drivas, Theodore G , Kaufman, Claire , Dickey, Melissa , Krock, Nolie , Smith, Karen L. , Kirkland, Kristi, Rodriguez‐Lopez, Josanna , Witkin, Alison S. , Hetts, Steven W. , Sisk, Bryan A. , Lu, An, Whitehead, Kevin J. , Drivas, Theodore G. , Dickey, Melissa , Boyce, Danielle M. , Pollak, Jeffrey

Mayo Clinic

Blood | March 17, 2026 | Volume: 148 | Issue: 4 | Pages: 417-432

10.1182/blood.2026033112 | PMID 41843464 Get It

Abstract Hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant vasculopathy affecting 1 in 5000 individuals, is the second most common inherited bleeding disorder worldwide. Despite this prevalence, comprehensive data on disease manifestations and complications remain limited. To address this gap, the US Congress allocated funding leading to the Comprehensive HHT Outcomes Registry of the United States (CHORUS), a prospective, 15-center longitudinal registry enrolling unselected patients with confirmed HHT. In this initial report, we describe findings from the first 600 participants, with a median age of 53 (range, 0-88) years and 60% female. Despite most participants developing typical HHT manifestations by age 13 years, the majority (63%) were not diagnosed until mid-to-late adulthood. Recurrent spontaneous epistaxis occurred in 95% of participants, chronic gastrointestinal bleeding in 30%, and heavy menstrual bleeding in 35% of postmenarche females, together resulting in moderate-to-severe mucosal bleeding in 76%. Iron deficiency and/or anemia were diagnosed in 68%, with 41% requiring IV iron and 25% requiring red cell transfusions. Serious complications of solid-organ arteriovenous malformations were frequent, including intracranial hemorrhage (3%), pulmonary hemorrhage (2%), venous thromboembolism (7%), arterial thromboembolism (11%), heart failure (7%), and pulmonary hypertension (7%). These data from CHORUS, the first national US registry of its kind, provide reliable, real-world estimates of the incidence, prevalence, and severity of numerous HHT manifestations and complications. HHT has a high burden of moderate-to-severe bleeding, anemia, thrombosis, and major neurologic and cardiopulmonary complications. There is a mean interval between first symptoms and diagnosis of &gt;2 decades, during which substantial, serious, and preventable HHT morbidity, including early intracranial hemorrhage, may occur. This trial was registered at clinicaltrials.gov as NCT06259292.
Return to Basketball After Primary Hip Arthroscopy for Femoroacetabular Impingement: Minimum 5-Year Follow-up
Mercurio, Angela M. , Iyer, Sanathan , Dancy, Malik, Levy, Bruce A., Hevesi, Mario, Krych, Aaron J., Okoroha, Kelechi R. , Krych, Aaron J. , Hevesi, Mario , Smith, John-Rudolph, Hevesi, Mario , Okoroha, Kelechi R , Krych, Aaron J , Mercurio, Angela , Smith, John-Rudolph H. , Dancy, Malik E. , Kang, Louis , Levy, Bruce A.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | March 16, 2026 | Volume: 14 | Issue: 3 | Pages: No page available

10.1177/23259671251397529 | PMID 41884689 Get It

Background: Femoroacetabular impingement (FAI) is a common injury experienced by basketball players. Surgical management with arthroscopic labral repair and femoral osteochondroplasty can lead to successful outcomes for athletes whose nonoperative management fails. Recent studies have demonstrated that athletes undergoing hip arthroscopy in the setting of FAI had favorable return-to-sport (RTS) and sport continuation outcomes. Purpose: To evaluate patient-reported outcome measures (PROMs) and RTS rates at minimum 5-year follow-up in basketball players after hip arthroscopy for FAI. Study Design: Case series; Level of evidence, 4. Methods: All active basketball players at the recreational, high school, and collegiate levels who underwent primary hip arthroscopy with labral repair for FAI between August 2009 and December 2019 were identified. Postoperative RTS, revision rates, and surgery satisfaction at final follow-up were evaluated. PROMs were also analyzed as follows: visual analog scale, Tegner Activity Scale, modified Harris Hip Score, Hip Outcome Score–Activities of Daily Living, and Hip Outcome Score–Sport. Results: Fifty-three patients (64 hips) were included with a mean ± SD age of 21.2 ± 6.0 years. Most athletes played recreational or high school basketball (85%), while 15% played college basketball. Forty-three patients attempted to return to basketball. Of these patients, 35 (81%) returned to basketball after surgery, with 32 (91%) returning to the same level of play. Patients who returned to basketball had significantly improved outcomes on the modified Harris Hip Score ( P = .006), Hip Outcome Score–Activities of Daily Living ( P = .007), Hip Outcome Score–Sport ( P = .004), Tegner Activity Scale ( P = .010), and visual analog scale with use ( P = .041) as compared with those who did not return. High school athletes had decreased odds of RTS when compared with recreational athletes ( P = .01). There was significant improvement in all PROMs from baseline to minimum 5-year follow-up ( P < .05). Conclusion: At minimum 5-year follow-up, basketball players demonstrated durable improvements in PROMs and an RTS rate of 81% after hip arthroscopy for FAI. The majority of athletes returned to the same level of competition. There were significantly improved PROMs in patients who returned to sport versus those who did not. High school athletes had decreased odds of RTS when compared with recreational athletes. However, body mass index, sex, age, alpha angle, and basketball position did not significantly correlate with RTS outcomes.
Early vs Late Surgical Intervention for Morel-Lavallée Injuries: A Pacific Coast Surgical Association Prospective Multicenter Study
Smith, Maren, Grigorian, Areg , Santorelli, Jarrett , Stephens, Daniel J, Minoza, Karen , Biffl, Walter L, Tillou, Areti , Nahmias, Jeffry, Group, the Morel-Lavallee Study, Balan, Naveen , Balan, Naveen , Dilday, Joshua C. , Biffl, Walter L. , Coimbra, Raul , Nahmias, Jeffry T.

Mayo Clinic

Journal of the American College of Surgeons | March 12, 2026 | Volume: 243 | Issue: 3 | Pages: 651-659

10.1097/xcs.0000000000001918 | PMID 42599047 Get It

BACKGROUND: Morel-Lavallée lesions (MLLs) are closed degloving injuries that occur throughout the body and present treatment challenges due to their rarity and variability in management. We aimed to compare characteristics and outcomes for MLL patients undergoing early (less than 48 hours) vs late (more than 48 hours) surgical intervention, hypothesizing decreased length of stay (LOS) with early intervention. STUDY DESIGN: Fifteen centers participated in this prospective observational study, including all adult patients who sustained a MLL and underwent surgery. No patients were excluded. Bivariate comparisons for early vs late intervention cohorts were performed. RESULTS: Of 150 MLL patients, 101 (67.3%) underwent early intervention. Both cohorts had comparable ages, BMI, vitals, Charlson Comorbidity Index, and injury severity scores (all p > 0.05). However, early intervention patients more commonly had abdominal (37% vs 6.3%, p < 0.001) MLLs, whereas late intervention patients more often had hip (16.7% vs 3.0%, p = 0.01) and thigh (41.7% vs 22%, p = 0.03) MLLs. Early patients had shorter ICU LOS (2 vs 5, p = 0.003) but statistically similar hospital LOS (12 vs 20, p = 0.06). There was no difference in wound-related complications (19.8% vs 24.5%, p = 0.51) or mean number of additional surgeries (p = 0.41) between cohorts. CONCLUSIONS: Over two-thirds of MLL patients underwent early operation. These patients had decreased ICU LOS and a statistically similar albeit clinically shorter overall LOS, despite similar demographics, comorbidities, injury severity, and number of additional surgeries. Therefore, early operation appears beneficial and should be pursued in MLL patients when clinically indicated and feasible.
MDB-29. Humanized iPSC models for group 3 medulloblastoma reveal key context-specific functions for MYC in remodeling the chromatin landscape.
Qadeer, Zulekha A. , Siegel, Dara, Hou, Elise, Beytagh, Mary C. , Westelman, Samantha, Gudenas, Brian , Smith, Kyle, Mohammed, Wazim, Wang, Linyu , Liu, John, Gaspar-Maia, Alexandre, Northcott, Paul, Weiss, William, Hou, Elise, Wang, Linyu, Huang, Miller , Gaspar‐Maia, Alexandre , Gilbert, Luke A. , Northcott, Paul A , Taylor, Michael D. , Weiss, William A.

Mayo Clinic

Neuro-Oncology Pediatrics | March 12, 2026 | Volume: 1 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuaf001.228 Get It

Abstract Medulloblastoma (MB) is one of the most prevalent malignant brain tumors in children, with tremendous cognitive and neuroendocrine disability among survivors. Group 3 (G3) MBs have poor overall survival at &lt; 50%, higher frequency of metastasis, and no targeted therapies. Amplification of MYC and activation of TGFβ signaling are frequent in G3MB. Remarkably, some tumors have no reported mutations, suggesting roles for epigenetic mechanisms in driving disease. We have generated novel humanized models for G3MB by transducing neuroepithelial stem cells (NESC) derived from human induced pluripotent stem (iPSC) cells with TGFβ effectors alone and/or in combination with MYC, prioritizing combinations observed in patients. We determined that both MYC and TGFβ effectors drove tumor formation in vivo with the combination driving more aggressive tumors and higher frequency of metastasis. NESC-derived tumors clustered with human G3/G4MB, indicating our models recapitulated human disease. To decipher mechanisms of resistance, we integrated CUT&RUN for MYC genomic localization and histone PTMs with RNA-sequencing and discovered MYC-bound neural developmental genes repressed in MYC and TGFβR1-driven lines. Further interrogation identified JARID1B, a MYC binding partner, as a regulator of many of these repressed neural genes. We postulate that deregulation of MYC and context-specific targeting to the chromatin template culminates in transcriptional alterations that promote aggressive G3MB. To further investigating therapeutic vulnerabilities, we have performed a in vivo whole genome CRISPRi screen to reveal important drivers of malignancy, one of the first of it’s kind in brain tumors. We are functionally validating key candidate sgRNAs that were differentially significant in primary tumors and may also have key roles in driving metastasis. Excitingly, many sgRNAs identified from the screen were chromatin modifiers and may be important co-factors of MYC-mediated regulation on the epigenome. Collectively, our studies provide a critical framework for understanding mechanisms of resistance and the epigenetic landscape of MYC- and TGFβ-driven MB.